• Mashup Score: 0

    A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the

    Tweet Tweets with this article
    • Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/2FkNau6qQK

  • Mashup Score: 2

    A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the

    Tweet Tweets with this article
    • Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/2FkNau6qQK

  • Mashup Score: 2

    A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the

    Tweet Tweets with this article
    • Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/yEyp8CNbVn

    • Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/PO2cB2x258